secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0001493152-22-028556
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio terminates Chief Medical Officer Michael Dawson, effective Oct 11, 2022
--------------------------------------------------------------------------------

- Michael Dawson, MD, terminated as Chief Medical Officer effective October 11, 2022.
- No successor or interim CMO named in the filing.
- Departure may impact clinical development strategy for Palisade Bio (PALI).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222028556/0001493152-22-028556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222028556/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-028556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer